Transcatheter Heart Valve (THV) MarketPosted by ahila on May 1st, 2018 Transcatheter heart valves (THV) are used to replace the heart valves with a prosthetic valve for treatment of severe aortic stenosis and mitral regurgitation. These heart valve diseases can be congenital or acquired later in life due to age related life style changes and may be other underlying diseases. If these are not treated can cause heart failure, stroke, blood clots, or death due to sudden cardiac arrest. According to WHO, by 2050, the world’s population aged 60 years and older is expected to total 2 billion, up from 900 million in 2015, who are more susceptible to the valve heart disease. The prime driver for the transcatheter heart valves (THV) market is rising demand for less invasive procedure for high-risk patients such as patients having multiple chronic diseases, growing prevalence of heart valve disorders. Moreover, increased incidences of heart diseases and technological advances in transcatheter heart valves (THV) driving the market. However, high costs of transcatheter heart valves, associated risks in implantation of transcatheter, slipping of valves, and misplacement of catheters are decreasing the acceptance in patients and affecting the market growth negatively.
A sample of this report is available upon request @ Transcatheter heart valve (THV) market segmented on the basis of product type, by approach, and end-user By product type, transcatheter heart valve market segmented into
By surgical procedure type, transcatheter heart valve market segmented into
By end-user, transcatheter heart valve market segmented into
To view TOC of this report is available upon request @ Like it? Share it!More by this author |